Caribou Biosciences, Inc. experienced a 45% share price decline after presenting puzzling results for their product candidate CB-010 in a Phase 1 clinical trial. CB-010 showed limited efficacy in ...
Caribou Biosciences announces new clinical trials and leadership appointments, highlighting progress in CAR-T therapy for various cancers and lupus. Caribou Biosciences, Inc. announced the initiation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results